Breaking News: Regen BioPharma Inc. Chairman Discusses the Rationale for Pursuing Autoimmune Indications by Activating the Nuclear Receptor NR2F6

Regen BioPharma Inc. (OTCQB: RGBP) (OTCQB: RGBPP) commenced a program to identify small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Regen BioPharma believes that by inhibiting the NR2F6 nuclear receptor, one can unleash the cancer-killing potential of a patient’s own immune system. Regen is also engaged in the identification of small molecules which activate the NR2F6 nuclear receptor that can be utilized to develop small molecule therapies for autoimmune disorders

“The rationale for activating the NR2F6 nuclear receptor (also known as a checkpoint) is straightforward – if inhibiting the checkpoint activates the immune system and thus helps kill cancer cells, then conversely, activating the checkpoint should suppress the immune system and thus be useful in diseases where the immune system is over-activated, such as rheumatoid arthritis, lupus, colitis and many other autoimmune diseases,” says David Koos, Ph.D., Chairman and CEO of Regen. “Our program stands out because we are working with small molecules delivered in pill form. Other biotechnology companies are focused on antibodies that have much more cumbersome delivery methods (hospital stays with IV injections, etc.). The benefits of small molecules are many, including cost of manufacturing, flexibility in dosing and routes of administration, potential control of toxicity and intellectual property protection.”

There are currently about 9 companies working on activating immune checkpoints, but Regen appears to be the sole company known to be working on utilizing small molecules to activate immune checkpoints (  


Sponsored Content Release. Click for Full Disclosure


Leave a Comment